References
- Blois M (1958): Antioxidant determination by the use of a stable free radical. Nature 181: 1199–1200.
- Bresson-Rival D, Mariotte A M, Boumendjel A, Perrier E (1999): Nouveaux esters de flavonoids, leur utilisation en cosmétique, dermopharmacie, en pharmacie et en agroalimentaire. French Patent 2: 663, 778.
- Burke T R, Jr (1992): Protein-tyrosine kinase inhibitors. Drugs of the Future 17: 119–131.
- Cunningham B D, Threadgill M D, Groundwater P W, Dale I L, Hickman J A (1992): Synthesis and biological evaluation of a series of flavone designed as inhibitors of protein tyrosine kinases. Anticancer Drug Des 7: 365–384.
- De Azevedo F W Mueller-Dieclanann H J, Schulze-Gahmen U, Worland P J, Sausville E H (1996): Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci USA 93: 2735–2740.
- Doucet C, Pochet L, Thierry N, Pirotte B, Delarge J, Reboud-Ravaux M (1999): 6-Substituted 2-oxo-2H-1-henzopyran-3-carboxylic acid as a core structure for specific inhibitors of human leukocyte elastase. J Med Chem 42: 4161–4171.
- Harhorne J R (1994): The Flavonoids: Advances in Research Since 1986. London, Chapman and Hall.
- Huebner P F (1976): Determination of elastolytic activity with elastin-rhodamine. Anal. Biochem 74: 419–429.
- Jovanovic S, Steenken S, Tosic M, Marjanovic B, Simic M (1994): Flavonoids as anti-oxydants. J Am Chem Soc 116: 4846–4851.
- Sicheri F, Moarefi I, Kuriyan J (1997): Crystal structure of the Src family tyrosine kinase Hck. Nature 385: 602–609.
- Silverman R B (1992): The Organic Chemistry of Drug Design and Drug Action. San Diego, Academic Press.